High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Adjusted EPS of $7.78 beats expectations, leading to a full-year outlook increase to at least $30.45, as Specialty and Care Services surge 22%.
Cigna delivers an earnings and revenue beat as Cigna Healthcare fuels growth, while the company raises its 2026 EPS outlook despite higher pharmacy costs.
The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cigna (CI) delivered earnings and revenue surprises of +2.64% and +0.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Health insurance company Cigna (NYSE:CI) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 6.8% year on year to $71.67 billion. Its non-GAAP profit of $7.78 per share was 2.4% above analysts’ consensus estimates.
Investing.com -- The Cigna Group (NYSE:CI) reported second-quarter earnings and revenue that exceeded analyst expectations, while raising its full-year outlook, though shares fell 1% premarket following the announcement.
Cigna Group lifted its outlook and reported a higher profit in the second quarter, driven by growth in both its healthcare and pharmacy-benefit businesses.
Cigna Group will report its earnings on Thursday under its new chief executive, Brian Evanko. It’s transitioning its pharmacy benefits business to a rebate-free model.
Most S&P 500 investors assume they own the market, but one overlooked mechanism quietly determines how much cash actually flows back to shareholders, and ignoring it this year has carried a measurable price.
CI's Q2 earnings are likely to face pressure from fewer insured medical customers and a higher MCR despite expected revenue growth.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cigna (CI), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
The healthcare giant looks expensive on today's numbers, but a patient investor is effectively buying it at a significant discount to that price.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
UnitedHealth's stock is flying high after it raised guidance, but on its latest earnings call, analysts zeroed in on an underlying margin divergence running right through the business.
The stock is trading near 52-week highs, but under the surface, commercial segment cost trends are creating headwinds.
Cigna Group (CI) continues to draw investor attention after recent share moves, with the stock last closing at US$281.45. The company’s mixed return profile over various periods is prompting closer scrutiny of its valuation and fundamentals. See our latest analysis for Cigna Group. Recent trading shows some cooling in momentum for Cigna Group, with the 1 day share price return slipping 0.83% and the 7 day return down 4.09%. The 5 year total shareholder return of 32.51% points to a steadier...
The sticker price on CVS shares looks high, but the real question is what it costs on the earnings expected two years from now.
The health insurer raised its forecast after a solid quarter, but investors focused on the one business so broken it’s forcing a strategic retreat.
Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.
The stock is priced for strength, but a deep and persistent drag from one of its largest divisions could challenge the optimistic narrative.
The stock's current valuation looks steep, but for a patient holder, the price tag on future earnings tells a very different story.
UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs and gave a big boost to its full-year outlook. Humana, Centene and CVS Health all got a sizable lift from the warm reception for UnitedHealth's earnings report.
The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.
Check out the companies making headlines yesterday:
(Updates with Claritev's response in the fourth paragraph.) The US Justice Department recently se
(Update with the Justice Department's response to a request for comment in the third paragraph.)
Shares of health insurance company Cigna (NYSE:CI) jumped 3.5% in the afternoon session after analyst firm Bernstein raised its price target on the stock to $381 from $371, citing a positive outlook. Bernstein maintained its "Outperform" rating on Cigna.
The health care giant commands a premium price over its rivals, but its core numbers tell a different story. Is the market seeing a future that isn't in the results yet.
The health care giant sent a torrent of cash to its owners, but the stock itself told a very different story about the last five years.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
